Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Select Rare CNS Cancers
Phase of Trial: Phase II
Latest Information Update: 04 May 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications CNS cancer; Ependymoma; Germ cell and embryonal neoplasms; Glioma; Gliosarcoma; Medulloblastoma; Meningioma; Papilloma
- Focus Therapeutic Use
- 28 Apr 2018 Planned primary completion date changed from 1 Dec 2021 to 31 Dec 2019.
- 30 Jun 2017 Status changed from not yet recruiting to recruiting.
- 28 Jun 2017 Planned initiation date changed from 3 Jul 2017 to 4 Jul 2017.